• Securing a comparative edge in terms of "safety" and "cost competitiveness" over existing vaccine development technologies
• Next-generation core source technology for immunotherapy that includes all of the advantages of antibody drugs, cell therapy products, and gene medicines
• Technology with an extremely great “scalability" capable of developing new vaccines in a short period of time by using genetic recombination technologies

---

Platform technology for the development of oral treatment vaccines and preventive vaccines

• Induces antigen-specific immunities by absorbing antigens (entire protein or some peptides) into a body with lactic acid bacteria as its transporter : Induces antigen (target)-specific CTL (Cytotoxic T Lymphocyte) immunities or antibodies (Ab)
• Technology with immunological characteristics that prevents and treats diseases or symptoms by inducing voluntary antigen-antibody reactions inside a body to neutralize or eliminate target proteins and. by increasing the activation of cytotoxicity, to remove heteromorphic cells

Medicine under development and diseases to be treated

Pursuit of pipeline extension

• New candidate medicine substances under development to replace follow-up antibody drugs, including medicine for the treatment of rare diseases
• Treatment vaccines for solid cancers including female cancers (cancer immunotherapy) and for metabolic diseases, etc.